Logo

Transforming good science
into great medicine
for rare genetic diseases.

Deep and diversified product pipeline

Developing multiple clinical-stage programs in parallel                                  

Focused on serious rare and ultra-rare diseases

Working with patients and medical professionals to treat rare diseases

Dedicated to creating new treatments 

Join a high-performance team focused on rare diseases

April 16, 2019
Ultragenyx Announces UX007 Granted Fast Track Designation and Rare Pediatric Disease Designation by U.S. FDA for Treatment of Long-Chain Fatty Acid Oxidation Disorders

April 11, 2019
Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York

March 26, 2019
Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Camille Bedrosian, M.D.
      • Wladimir Hogenhuis, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
      • Shehnaaz Suliman, M.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for TIO
    • UX007 for FAOD
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Stock Information
      • Analyst Coverage
    • Investor FAQ
    • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
    • Driving Directions
  • Home
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Camille Bedrosian, M.D.
      • Wladimir Hogenhuis, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
      • Shehnaaz Suliman, M.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for TIO
    • UX007 for FAOD
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Stock Information
      • Analyst Coverage
    • Investor FAQ
    • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
    • Driving Directions
  • Privacy Policy
© 2019 Ultragenyx PharmaceuticalWebsite Design: Hane Chow, Inc.
  • Privacy Policy